<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292719</url>
  </required_header>
  <id_info>
    <org_study_id>M14-567</org_study_id>
    <secondary_id>2014-003147-35</secondary_id>
    <nct_id>NCT02292719</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ombitasvir/ABT-450/r
      with sofusbuvir with or without ribavirin in adults with Genotype 2 Chronic Hepatitis C
      Virus (HCV)infection or Genotype 3 HCV infection With or Without Cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment</measure>
    <time_frame>12 weeks after the last dose of active drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid greater than or equal to the lower limit of quantification after hepatitis C virus ribonucleic acid less than lower limit of quantification or confirmed 1 log10 IU/mL increase from nadir in hepatitis C virus ribonucleic acid at any time point during treatment, or failure to suppress during treatment with at least 6 weeks of treatment (defined as active study drug duration â‰¥ 36 days) of treatment for 12-week and 8-week treatment or at least 26 days of treatment for 6-week treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic relapse after treatment</measure>
    <time_frame>Up to 12 weeks after the last actual dose of active study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification between the end of treatment and 12 weeks post treatment among subjects completing treatment and with HCV RNA less than the lower limit of quantification at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/ABT-450/r</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HCV infection prior to study enrollment.

          2. Screening laboratory results from the central clinical laboratory indicating HCV
             genotype 2 or 3 infection only (no mixed genotype).

          3. Absence OR presence of cirrhosis.

          4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular
             carcinoma (HCC)

        Exclusion Criteria:

          1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus
             antibody

          2. Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse.

          3. Current enrollment in another clinical study, previous enrolment in this study, or
             previous use of any investigational or commercially available anti-HCV therapy (other
             than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir,
             boceprevir, ABT-450, or ombitasvir (ABT-267).

          4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.

          5. Abnormal lab tests.

          6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malin Folmerz</last_name>
    <phone>+46 8-546-56-700</phone>
    <email>malin.folmerz@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Travis Yanke</last_name>
    <phone>1-847-938-0976</phone>
    <email>travis.yanke@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132435</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132434</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132014</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132014, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132436</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132436, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132013</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132013, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132011</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132011, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132012</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132012, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>November 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Genotype 3</keyword>
  <keyword>Non-cirrhotic</keyword>
  <keyword>Cirrhotic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
